Last update Dec. 10, 2022

Prifinium Bromide

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is an antimuscarinic/anticholinergic with peripheral effects similar to those of atropine. It has antispasmodic and antiemetic properties and has been used in irritable bowel syndrome. Oral, subcutaneous, intramuscular or intravenous administration 2 to 4 times a day.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (large volume of distribution, short half-life, and low oral bioavailability) make it unlikely that it will pass into breast milk in clinically significant amounts.

Intestinal absorption is practically non-existent (Noguchi 1983), so the little that may pass into breast milk will not be absorbed by the infant.

Although antimuscarinics can decrease prolactin production (Müller 1983, Masala 1982), once lactation is established, milk production depends more on the repeated stimulation of suckling than on prolactin levels.

The literature on this drug is scarce and it is sold in few countries.

Alternatives

  • Atropine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Linaclotide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Otilonium Bromide (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Rifaximin ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Prifinium Bromide in other languages or writings:

Group

Prifinium Bromide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Prifinium Bromide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 3.4 %
Molecular weight 386 daltons
VD 1.9 l/Kg
Tmax 2 - 3 hours
2.18 hours

References

  1. Müller EE, Locatelli V, Cella S, Peñalva A, Novelli A, Cocchi D. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs. 1983 Apr;25(4):399-432. Review. Abstract
  2. Noguchi H, Tokuma Y, Tamura Y. Pharmacokinetics of prifinium bromide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1983 May;21(5):213-7. Abstract
  3. Masala A, Alagna S, Devilla L, Rovasio PP, Rassa S, Faedda R, Satta A. Muscarinic receptor blockade by pirenzepine: effect on prolactin secretion in man. J Endocrinol Invest. 1982 Jan-Feb;5(1):53-5. Abstract

Total visits

5,377

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM